Charles River Laboratories (CRL)
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$288.50-1.65%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · CRL
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $288 CRL trades at 29× p/e, below its 34× p/e peer median, but our blended $272 fair value sits below the price. It's a high-confidence read. Analysts target $192–$300. Even valued only for durable growth at sustainable margins, it's worth about $325 — above today's price, so the premium reflects that growth case, not pure multiple expansion. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $250.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $137.72 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $141.72 | — | — | Hist. CAGR | high |
| graham number | 12M | $114.90 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Below average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$192.00 – $300.00 (median $250.00) · 16 analysts · as of 2026-08-10
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price you pay about 536% over what the business is worth with no growth; closing that gap needs roughly — years of the forecast growth to come through. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $3.28/sh owner earnings.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $308.97 |
| 18.0 |
| 16.93 |
| TTM |
| high |
| Peer P/FCF | 12M | $267.58 | 34.7 | 7.72 | TTM | high |
| Peer P/E | 12M | $335.65 | 33.9 | 9.90 | TTM | high |
| Peer P/S | 12M | $475.22 | 5.7 | 83.28 | TTM | high |
| PEG | 12M | $758.00 | 76.6 | 9.90 | TTM | high |
| residual income | 12M | $74.19 | — | — | TTM | high |
| triangulated | 12M | $355.52 | 33.9 | 10.49 | Triangulated | high |
| Peer P/FCF | 3Y | $342.70 | 34.7 | 9.88 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $439.28 | 33.9 | 12.96 | Analyst | medium |
| Peer P/S | 3Y | $489.62 | 5.7 | 85.80 | guidance | medium |
| PEG | 3Y | $992.03 | 76.6 | 12.96 | Analyst | medium |
| Peer P/FCF | 5Y | $404.17 | 34.7 | 11.66 | Hist. CAGR(prov.) | medium |
| Peer P/E | 5Y | $448.11 | 33.9 | 13.22 | Analyst | medium |
| Peer P/S | 5Y | $499.47 | 5.7 | 87.52 | guidance | medium |
| PEG | 5Y | $1011.97 | 76.6 | 13.22 | Analyst | medium |